Response to the Letter to the Editor Entitled “Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy”

Giri K, Glassock RJ, Fervenza FC. Response to the Letter to the Editor Entitled "Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy". Kidney Int Rep. 2026 Jun 6;11(9):106658. doi: 10.1016/j.ekir.2026.106658. PMID: 42541134; PMCID: PMC13427534.


Related Posts